Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors

Vaccine

Volumn 26, Issue 41, 2008, Pages 5315-5320

  Sewell, Duane A ^a   Pan, Zhen Kun ^a   Paterson, Yvonne ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer vaccines; HPV 16; Listeria

Indexed keywords

CANCER VACCINE; HUMAN PAPILLOMA VIRUS TYPE 16 VACCINE; LISTERIA BASED CANCER VACCINE; LISTERIOLYSIN O; LM ACTA E7 VACCINE; LM LLO E7 VACCINE; LM NP VACCINE; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; WART VIRUS VACCINE; BACTERIAL VACCINE; GAMMA INTERFERON; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGICAL TOLERANCE; LD 50; LISTERIA; MOUSE; NONHUMAN; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; THYROID TUMOR; TRANSGENIC MOUSE; TUMOR GROWTH; VACCINE PRODUCTION; ANIMAL; ANTIBODY PRODUCTION; CD8+ T LYMPHOCYTE; DISEASE MODEL; IMMUNOLOGY; THYROID GLAND;

ANIMALS; ANTIBODY FORMATION; BACTERIAL VACCINES; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; INTERFERON-GAMMA; LISTERIA; MICE; MICE, TRANSGENIC; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; SPLEEN; THYROID GLAND; THYROID NEOPLASMS;

EID: 50849136160     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.036     Document Type: Article

References (17)

1. Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92 9 (2000) 709-720
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
3. Ressing M.E., van Driel W.J., Celis E., Sette A., Brandt M.P., Hartman M., et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 56 3 (1996) 582-588
4. Evans E.M., Man S., Evans A.S., and Borysiewicz L.K. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 57 14 (1997) 2943-2950
5. Tindle R.W. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2 1 (2002) 59-65
6. Gunn G.R., Zubair A., Peters C., Pan Z.K., Wu T.C., and Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 167 11 (2001) 6471-6479
7. Sewell D.A., Shahabi V., Gunn III G.R., Pan Z.K., Dominiecki M.E., and Paterson Y. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res 64 24 (2004) 8821-8825
8. Souders N.C., Sewell D.A., Pan Z.K., Hussain S.F., Rodriguez A., Wallecha A., et al. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immunol 7 (2007) 2
9. Sewell D.A., Douven D., Pan Z.K., Rodriguez A., and Paterson Y. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Otolaryngol Head Neck Surg 130 1 (2004) 92-97
10. Pan Z.K., Ikonomidis G., Lazenby A., Pardoll D., and Paterson Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat Med 1 5 (1995) 471-477
11. Ghim S.J., Sundberg J., Delgado G., and Jenson A.B. The pathogenesis of advanced cervical cancer provides the basis for an empirical therapeutic vaccine. Exp Mol Pathol 71 3 (2001) 181-185
12. Pan Z.K., Weiskirch L.M., and Paterson Y. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res 59 20 (1999) 5264-5269
13. Yoshimura K., Jain A., Allen H.E., Laird L.S., Chia C.Y., Ravi S., et al. Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res 66 2 (2006) 1096-1104
14. Kaufmann S.H. Immunity to intracellular bacteria. Annu Rev Immunol 11 (1993) 129-163
15. Barber E.M., Fazzari M., and Pollard J.W. Th1 cytokines are essential for placental immunity to Listeria monocytogenes. Infect Immun 73 10 (2005) 6322-6331
16. Freeman M.M., and Ziegler H.K. Simultaneous Th1-type cytokine expression is a signature of peritoneal CD4+ lymphocytes responding to infection with Listeria monocytogenes. J Immunol 175 1 (2005) 394-403
17. Singh R., and Paterson Y. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy. Expert Rev Vaccines 5 4 (2006) 541-552